Aclaris Therapeutics
ACRS
103 hedge funds and large institutions have $163M invested in Aclaris Therapeutics in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 40 reducing their positions, and 7 closing their positions.
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
25% more capital invested
Capital invested by funds: $130M → $163M (+$32.3M)
7% more funds holding
Funds holding: 96 → 103 (+7)
5.75% less ownership
Funds ownership: 84.84% → 79.09% (-5.8%)
35% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.23M |
| 2 |
Goldman Sachs
New York
|
+$1.39M |
| 3 |
TBWA
Three Bridge Wealth Advisors
Los Altos,
California
|
+$1.25M |
| 4 |
Morgan Stanley
New York
|
+$936K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$651K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.58M |
| 2 |
Millennium Management
New York
|
-$3.98M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1M |
| 4 |
D.E. Shaw & Co
New York
|
-$745K |
| 5 |
Two Sigma Advisers
New York
|
-$722K |
ACRS Hedge Fund Activity: Q3 2025 in Review
103 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2025, worth a combined $163M — up 25% from $130M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ACRS positions and 7 closed out — a net gain of 8 holders — while 26 added to existing stakes and 40 trimmed.
The largest buyer was Ameriprise, opening a new position worth an estimated $2.23M. The largest seller was Adage Capital Partners, cutting an estimated $7.58M.
- 103 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2025, up from 96 in Q2 2025.
- Funds reported $163M of Aclaris Therapeutics stock for Q3 2025, up 25% quarter-over-quarter.
- 15 funds opened new Aclaris Therapeutics positions in Q3 2025 and 7 closed out, a net change of +8 holders.
- The largest Aclaris Therapeutics buyer in Q3 2025 was Ameriprise, an estimated $2.23M added.
- The largest Aclaris Therapeutics seller in Q3 2025 was Adage Capital Partners, an estimated $7.58M sold.
Based on aggregated 13F filings for Q3 2025.